Full Press Release Details
SAN DIEGO , May 20, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) announced today that W. Thomas Mitchell has notified the Company that he is retiring from the Board of Directors effective just prior to the 2016 Annual Meeting of Shareholders. Mr. Mitchell has been a member of the Board of Directors for over thirteen years serving in various capacities on the audit, compensation, and nominating and corporate governance committees.
"Tom has been an integral member of the Board and played an instrumental role in helping build Neurocrine to the company it is today," said Kevin C. Gorman , President and Chief Executive Officer. "We wish him well in retirement, and want to thank him for his years of dedication and advice."
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and valbenazine, a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company.
Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com .
SOURCE Neurocrine Biosciences, Inc.